Welcome to our dedicated page for Treace Medical Concepts SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Treace Medical Concepts, Inc. (TMCI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed medical technology company focused on bunion and related midfoot deformities, Treace uses these filings to report financial results, material agreements, governance changes and risk factors relevant to TMCI stockholders.
Investors can review annual reports on Form 10‑K for a detailed discussion of Treace’s business, including its Lapiplasty 3D Bunion Correction System, Adductoplasty Midfoot Correction System, minimally invasive Nanoplasty and Percuplasty systems, SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants, IntelliGuide patient specific technology, and associated risk factors and market considerations. Quarterly reports on Form 10‑Q provide interim financial statements, management’s discussion and analysis and updates on operations and liquidity.
Current reports on Form 8‑K capture specific material events, such as the entry into new senior secured term loan and revolving credit agreements, repayment and termination of prior credit facilities, earnings releases for quarterly periods and changes in the composition or roles of the board of directors. These filings outline key terms of financing arrangements, including collateral, interest rates, covenants and potential implications for dividend payments.
Users can also monitor proxy statements and related materials for information on governance, board structure and executive compensation, as well as Section 16 filings such as Form 4 for reports of insider transactions in TMCI shares. Stock Titan’s platform pairs these documents with AI‑powered summaries that explain complex sections, highlight notable items and help readers quickly understand how new filings may relate to Treace’s bunion‑focused business, financial condition and capital structure.
With real‑time updates from EDGAR and structured access to key forms, this page serves as a central resource for analyzing TMCI’s regulatory history and ongoing disclosure record.
Treace Medical Concepts, Inc. Chief Financial Officer Mark Hair reported a routine share disposition related to tax withholding. On this Form 4, 11,547 shares of common stock were withheld to cover tax obligations, leaving him with 952,002 shares, including 786,691 restricted stock units.
Treace Medical Concepts, Inc. announced preliminary first quarter 2026 results and a leadership change. For the three months ended March 31, 2026, preliminary revenue is expected to be in the range of $47.0 million to $47.2 million. Preliminary cash, cash equivalents and marketable securities are expected to total about $51.9 million as of March 31, 2026, up from $48.4 million as of December 31, 2025 and a smaller increase in the first quarter of 2025.
The company updated its full-year 2026 revenue guidance to $202 million to $212 million, slightly raising the low end of the prior outlook to reflect continued case volume growth and headwinds from product and price mix in its expanded bunion portfolio. Treace also disclosed that Chief Commercial Officer Gaetano M. Guglielmino will depart as of April 8, 2026. His responsibilities will be absorbed by existing staff, with the Senior Vice President, Sales reporting directly to the Chief Executive Officer. Guglielmino will serve as an independent consultant through January 31, 2027 under a paid consulting agreement that includes a monthly fee, COBRA premiums, a pro-rated 2026 bonus, apartment rent coverage until lease assignment, and continued vesting of prior equity awards.
Treace Medical Concepts, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on May 19, 2026 at 11:00 a.m. Eastern Time. Stockholders will elect three Class II directors, approve on an advisory basis executive compensation, and ratify Grant Thornton LLP as independent auditor for 2026.
The Board recommends voting FOR all three proposals. The record date is March 23, 2026, covering 64,784,436 outstanding common shares. Treace highlights a bunion-focused portfolio now addressing all four bunion classes, with over 134,000 Lapiplasty patients treated since late 2015 and several new systems launched in 2025.
The company emphasizes a culture of integrity, a seven-member classified board with six independent directors, and human capital initiatives, including approximately 450 employees, internal promotions, low undesired turnover and high employee engagement relative to medical device and biotechnology peers.
Treace Medical Concepts, Inc. Chief Financial Officer Mark Hair reported an equity compensation grant of 100,000 performance stock units. Each PSU entitles him to one share of common stock upon vesting, reflecting a non-cash, compensation-related acquisition rather than an open-market purchase.
The PSUs were earned after the Compensation Committee certified achievement of a performance goal and will vest 25% on April 15, 2026 and 25% on each February 15 of 2027, 2028 and 2029, subject to his continued service. Following this award, he directly holds 963,549 shares of common stock, which include 811,691 restricted stock units.
Treace Medical Concepts Chief Legal & Compliance Officer Scot Michael Elder reported routine tax-withholding dispositions of company stock. On two March dates, a total of 1,850 shares of common stock were delivered to cover tax obligations. Following these transactions, Elder directly held 794,936 common shares. Footnotes indicate these holdings include restricted stock units.
Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported tax-withholding dispositions of company stock. On March 8 and March 10, 2026, a total of 1,797 shares of Common Stock were withheld to satisfy tax obligations, not sold on the open market.
After the March 10 transaction, he directly holds 704,677 shares of Common Stock, which includes 509,648 restricted stock units.
Treace Medical Concepts, Inc. director and Chief Executive Officer John T. Treace reported routine share withholding to cover tax obligations on equity awards. On two dates, a total of 7,083 shares of common stock were disposed of as tax-withholding transactions, not open-market sales. After these withholding events, he directly owns 7,004,550 common shares. Footnotes note that certain reported positions include 563,403 and 542,784 restricted stock units and that he disclaims beneficial ownership of shares held by his spouse and in various trusts where he or his spouse serve as trustee or co-trustee.
Treace Medical Concepts, Inc. Chief Financial Officer Mark Hair reported routine share dispositions tied to tax withholding on equity compensation. On March 8 and March 10, 2026, a total of 4,659 shares of common stock were withheld to satisfy tax liabilities, rather than sold on the open market.
After these transactions, Hair directly holds 863,549 shares of common stock, which includes 723,147 restricted stock units as of March 10, 2026. These entries reflect compensation-related mechanics, not discretionary buying or selling.
Treace Medical Concepts provides an overview of its business focused on surgical solutions for bunions and related midfoot deformities. The company highlights its flagship Lapiplasty 3D Bunion Correction System and complementary platforms such as Adductoplasty, Nanoplasty, Percuplasty, SpeedMTP, SpeedPlate, IntelliGuide, and a hammertoe system.
The filing describes a U.S.-focused commercial model with a 297-person field sales fleet and extensive surgeon training and direct-to-patient marketing, including National Bunion Day. It outlines large addressable markets for bunion surgery, summarizes favorable interim clinical data from ALIGN3D and Mini3D studies, details an active R&D pipeline including Lapiplasty Lightning, and notes 450 employees, robust patent and trademark portfolios, and a capital‑light manufacturing strategy using third‑party suppliers.